• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Effects of influenza antivirals on individual and population immunity over many epidemic waves

tetano

Editor, Senior Moderator
Epidemiol Infect. 2012 Mar 30:1-11. [Epub ahead of print]
Effects of influenza antivirals on individual and population immunity over many epidemic waves.
Pepin KM, Riley S, Grenfell BT.
Source

Department of Physics, Center for Infectious Disease Dynamics, Pennsylvania State University, University Park, PA, USA.
Abstract

SUMMARYAntivirals are an important defence against novel strains of influenza. However, the impact of widespread drug usage on strain circulation across multiple epidemic waves - via their impact on host immunity - is unknown despite antivirals having the likelihood of extensive use during a pandemic. To explore how drug usage by individuals affects population strain dynamics, we embedded a two-strain model of within-host dynamics within an epidemic model. We found that when 40% of hosts took drugs early during the infectious period, transmission was reduced by 30% and average levels of immunity by 2?9-fold (comparable to antibody concentrations), relative to 14% and 1?5-fold reductions when drugs were taken late. The novel strain was more successful relative to the resident strain when drugs were not taken, and an intermediate level of drug coverage minimized incidence in subsequent waves. We discuss how drug regimens, coverage and R0 could impact pandemic preparedness.

PMID:
22459665
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/22459665
 
Back
Top Bottom